Aoyama 2015.

Methods	Multicenter, randomised, double‐blind, placebo‐controlled trial (N = 165)
Participants	Patients with active, mild‐to‐moderate UC
Interventions	Group 1: budesonide foam (2 mg/25 mL) once daily Group 2: budesonide foam (2 mg/25 mL) twice daily Group 3: placebo
Outcomes	Primary outcome: remission at week 6 (rectal bleeding subscore = 0, endoscopic subscore < 1 and stool frequency subscore = 0 or decrease > 1)
Notes	Reported in abstract form only (unclear how many patients randomised to each group); not included in quantitative synthesis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Unclear risk	Reported in abstract form only